Wisconsin Institutes for Medical Research
Madison, Wisconsin, 53705, United States
NCT Number: NCT01516853
The purpose of this study is to validate magnetic resonance imaging as a biomarker of hepatic iron concentration (HIC). Excessive accumulation of iron in the body is highly toxic, specifically in the liver. Accurate, non-invasive assessment of HIC is needed for diagnosis, quantitative staging and treatment monitoring or hepatic iron overload.
Looking for future studies?
Notify Me10 year and older
All sexes
Observational
Madison, Wisconsin, 53705, United States
Excessive accumulation of iron in the body can result from abnormal intestinal absorption in hereditary hemochromatosis or repeated intravenous blood transfusions (ie: transfusional hemosiderosis). Excess body iron is highly toxic, and requires treatment aimed at reducing body iron stores. Measurement of body iron stores is critical for detection of iron overload, staging its severity and monitoring of iron-reducing therapies that are often extremely expensive (>$40,000/year) and carry their own toxicities. MRI has been shown to be very sensitive to the presence of iron. The investigators have developed an MRI-based method for rapid iron quantification (for instance, whole liver in a single breath-hold). The purpose of this work is to validate this new method using the FDA-approved Ferriscan technique (Resonance Health, Claremont, Australia) as a reference standard.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
Time frame: Up to 1 day
Accuracy of non-contrast R2*-MRI for measuring hepatic iron concentration.
Time frame: up to 1 day
Linear correlation between serum ferritin values and MRI R2* values
Time frame: up to 1 day
Linear correlation between serum ferritin values and FerriScan hepatic iron measurement.
Time frame: up to 1 day
Robustness of Proposed Method for Cardiac R2* Estimation. Measure variability of cardiac R2* with different imaging parameters.
University of Wisconsin, Madison
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02025543
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Palo Alto, California, United States
View Trial DetailsNCT00171301
Anemia, Anemia, Hemolytic
Cairo, Egypt
View Trial DetailsNCT07028112
Digestive System Diseases, Fibrosis
Paris, France
View Trial DetailsNCT02880033
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Lille, France
View Trial Details